{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:39:04Z","timestamp":1794713944215,"version":"4.9.1"},"reference-count":23,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016492","name":"Kiniksa Pharmaceuticals","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100016492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2022,9,29]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Polypharmacy management of recurrent pericarditis (RP) often involves long-term therapies, often with negative effects. Slow tapering of oral therapies is often required to avoid recurrence. A post hoc analysis of the phase III trial Rilonacept inHibition of interleukin-1 Alpha and beta for recurrent Pericarditis: a pivotal Symptomatology and Outcomes Study (RHAPSODY) evaluated investigator approaches to transitioning to IL-1 blockade monotherapy with rilonacept, which was hypothesised to allow accelerated withdrawal of common multidrug pericarditis regimens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>RHAPSODY was a multicentre (Australia, Israel, Italy, USA), double-blind, placebo-controlled, randomised-withdrawal trial in adults and adolescents with RP. Investigators initiated rilonacept at the labelled dose level and discontinued oral pericarditis therapies during the 12-week run-in; randomised patients received study drug as monotherapy. Time to rilonacept monotherapy was quantified in patients receiving multidrug regimens at baseline who achieved rilonacept monotherapy during run-in.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In 86 enrolled patients, mean time to rilonacept monotherapy was 7.9 weeks, with no recurrences. Of these, 64% (n=55) entered on multidrug regimens: non-steroidal anti-inflammatory drugs (NSAIDs) plus colchicine (44% (24\/55)), colchicine plus glucocorticoids (24% (13\/55)), or NSAIDs, colchicine, plus glucocorticoids (33% (18\/55)). Investigators transitioned patients receiving colchicine and glucocorticoids at baseline to rilonacept monotherapy without recurrence regardless of taper approach: sequential (n=14; median, 7.7 weeks) or concurrent (n=17; median, 8.0 weeks). Median time to rilonacept monotherapy was similar regardless of glucocorticoid dose and duration: \u226415\u2009mg\/day (n=21): 7.3 weeks; &gt;15\u2009mg\/day (n=18): 8.0 weeks; long-term (\u226528 days): 7.6 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Rapid discontinuation of oral RP therapies while transitioning to rilonacept monotherapy was feasible without triggering pericarditis recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03737110\">NCT03737110<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2022-321328","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T13:20:40Z","timestamp":1667222440000},"page":"297-304","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis"],"prefix":"10.1136","volume":"109","clinical-trial-number":[{"clinical-trial-number":"nct03737110","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Antonio","family":"Brucato","sequence":"first","affiliation":[{"name":"Department of Biomedical and Clinical Sciences \"Sacco\", University of Milano, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Clinical Development, Kiniksa Pharmaceuticals Corp, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil Allen","family":"Luis","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C","family":"Cremer","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangxing","family":"Zou","sequence":"additional","affiliation":[{"name":"Clinical Development, Kiniksa Pharmaceuticals Corp, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Insalaco","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Ospedale Pediatrico Bambino Ges\u00f9, Roma, Lazio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lewinter","sequence":"additional","affiliation":[{"name":"Cardiology Unit, University of Vermont Medical Center, Burlington, Vermont, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil S","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Lady Davies Carmel Medical Center, Haifa, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Minneapolis Heart Institute, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Pancrazi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Fatebenefratelli Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9240-8369","authenticated-orcid":false,"given":"Allan L","family":"Klein","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Imazio","sequence":"additional","affiliation":[{"name":"Cardiothoracic Department, Santa Maria della Misericordia University Hospital, Udine, Friuli-Venezia Giulia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7622-8851","authenticated-orcid":false,"given":"John F","family":"Paolini","sequence":"additional","affiliation":[{"name":"Clinical Development, Kiniksa Pharmaceuticals Corp, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"2025100706584331000_109.4.297.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv318"},{"key":"2025100706584331000_109.4.297.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.07.039"},{"key":"2025100706584331000_109.4.297.3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejim.2021.09.002","article-title":"Recent advances in pericarditis","volume":"95","author":"Bizzi","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2025100706584331000_109.4.297.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208536"},{"key":"2025100706584331000_109.4.297.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.542738"},{"key":"2025100706584331000_109.4.297.6","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.14.2093"},{"key":"2025100706584331000_109.4.297.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.12763"},{"key":"2025100706584331000_109.4.297.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.021"},{"key":"2025100706584331000_109.4.297.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.761064"},{"key":"2025100706584331000_109.4.297.10","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"2025100706584331000_109.4.297.11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1218"},{"key":"2025100706584331000_109.4.297.12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1710"},{"key":"2025100706584331000_109.4.297.13","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.17.1987"},{"key":"2025100706584331000_109.4.297.14","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jval.2021.04.345","article-title":"PCV5 risk factors associated with recurrence and Corticosteroid-Associated adverse events in patients with recurrent pericarditis","volume":"24","author":"Schwier","year":"2021","journal-title":"Value Health"},{"key":"2025100706584331000_109.4.297.15","doi-asserted-by":"crossref","unstructured":"Schwier NC , Luis SA , Hu X , et al . Risk factors associated with recurrence and corticosteroid-associated adverse events in patients with recurrent pericarditis [poster]. Presented at: Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 17-20, 2021.","DOI":"10.1016\/j.jval.2021.04.345"},{"key":"2025100706584331000_109.4.297.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3800"},{"key":"2025100706584331000_109.4.297.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027892"},{"key":"2025100706584331000_109.4.297.18","unstructured":"Regeneron Pharmaceuticals . Arcalyst [package insert]. Tarrytown, NY, 2016."},{"key":"2025100706584331000_109.4.297.19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/heartjnl-2020-317928","article-title":"Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial","volume":"107","author":"Klein","year":"2020","journal-title":"Heart"},{"key":"2025100706584331000_109.4.297.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.07.004"},{"key":"2025100706584331000_109.4.297.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.01.065"},{"key":"2025100706584331000_109.4.297.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205990"},{"key":"2025100706584331000_109.4.297.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.15826"}],"updated-by":[{"DOI":"10.1136\/heartjnl-2022-321328corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000}}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2022-321328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:24:48Z","timestamp":1759847088000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2022-321328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,1,27]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/heartjnl-2022-321328"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2022-321328","relation":{"correction":[{"id-type":"doi","id":"10.1136\/heartjnl-2022-321328corr1","asserted-by":"object"}]},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]}}}